Eton Pharmaceuticals (NASDAQ:ETON) announced its quarterly earnings data on Thursday. The company reported ($0.65) earnings per share (EPS) for the quarter, Bloomberg Earnings reports.
NASDAQ:ETON traded down $0.09 during midday trading on Friday, hitting $6.00. The stock had a trading volume of 950 shares, compared to its average volume of 18,753. Eton Pharmaceuticals has a one year low of $5.90 and a one year high of $6.68.
In other news, CEO Sean Brynjelsen acquired 10,000 shares of the business’s stock in a transaction that occurred on Thursday, November 15th. The shares were purchased at an average cost of $6.00 per share, for a total transaction of $60,000.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO William Wilson Troutman acquired 5,000 shares of the business’s stock in a transaction that occurred on Thursday, November 15th. The stock was purchased at an average price of $6.00 per share, for a total transaction of $30,000.00. The disclosure for this purchase can be found here.
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical product using the U.S. Food and Drug Administration's 505(b)(2) regulatory pathway. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products.
Featured Article: The Role of a Fiduciary and Individual Investors
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.